IL1B and colitis: As shown in Fig. 2e, ginsenoside Rg1 has been reported to inhibit the release of pro-inflammatory cytokines (IL-1β and TNF-α) by upregulating the expression of NLRP2 and then weaken the inflammatory response of DSS-induced colitis in mice [49].